Seasonal Trends in Palivizumab Compliance in High-Risk Infants Before, During, and After COVID-19 Restrictions
Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 31.03.2026 · 23 (1) · 14-21
DOI: 10.38136/jgon.1712772 ↗Kurz gefasst
Fachartikel in der Zeitschrift Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, online erschienen am 31.03.2026. Verfasst von Batuhan Yeke. Die Arbeit nennt 1 Literaturangaben.
Abstract (Originalsprache)
Aim
This study aimed to evaluate compliance with palivizumab prophylaxis in high-risk infants before and after the COVID-19 pandemic and to assess its effect on RSV and other respiratory infections. Materials and Methods: This retrospective observational study included 626 high-risk infants who received at least one dose of palivizumab at Ankara Bilkent City Hospital’s NICU between October 2019 and April 2023. Compliance was assessed by evaluating whether doses were administered at 30 ± 5-day intervals. Infants receiving all scheduled doses were classified as full prophylaxis (n=548, 87.5%), while those missing at least one dose were classified as partial prophylaxis (n=78, 12.5%). RSV and non-RSV infection and hospitalization rates were compared. Data were obtained from hospital records and interviews with parents.
Results
While 87.5% received full prophylaxis, only 65.2% followed the recommended dosing intervals. Partial compliance was mostly due to family neglect or hospitalization. RSV infections occurred more frequently in the partial group (9% vs. 4.6%), though the difference was not statistically significant. Non-RSV pneumonia and bronchiolitis rates were significantly higher in partially compliant infants (p<0.05). Compliance rates declined after the pandemic, and higher RSV incidence was observed in infants with siblings in daycare and in smoking households.
Conclusion
Full compliance with palivizumab prophylaxis significantly reduces RSV and non-RSV respiratory infections and related hospitalizations. The pandemic disrupted prophylaxis adherence and may have contributed to increased RSV incidence. Socioeconomic and environmental factors play a crucial role in ensuring compliance.
Zitieren
APA
Yeke, B. (2026). Seasonal Trends in Palivizumab Compliance in High-Risk Infants Before, During, and After COVID-19 Restrictions. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, 23(1), 14-21. https://doi.org/10.38136/jgon.1712772
Vancouver
Yeke B. Seasonal Trends in Palivizumab Compliance in High-Risk Infants Before, During, and After COVID-19 Restrictions. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi. 2026;23(1):14-21. doi:10.38136/jgon.1712772
BibTeX
@article{Yeke2026,
author = {Yeke, Batuhan},
title = {Seasonal Trends in Palivizumab Compliance in High-Risk Infants Before, During, and After COVID-19 Restrictions},
journal = {Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi},
year = {2026},
volume = {23},
number = {1},
pages = {14--21},
doi = {10.38136/jgon.1712772}
}
EUVIMED